Nexstim Plc (NXTMH.HE)
- GlobeNewswire
Health Canada Approves Nexstim NBS 6 System for Treatment of MDD
Press release, Helsinki, 6 May 2024 at 9 AM (EEST) Health Canada Approves Nexstim NBS 6 System for Treatment of MDD Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received approval from Health Canada for the marketing and commercial distribution of its NBS 6 system for the treatment of Major Depressive Disorder (MDD). Released in the EU and the United States in 2023, the NBS 6 is a new generation Nexstim system. The NBS 6 is currently FDA-approved for the treatment of major depressive diso
- GlobeNewswire
Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market
Press release, Helsinki, 3 May 2024, 10 AM (EEST) Nexstim, Inc. and Inomed Inc. Enter into Strategic Alliance Agreement for US Market Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") announces that Nexstim, Inc. has signed a non-exclusive strategic alliance agreement with Inomed Inc. for the purpose of strengthening the collaboration of Marketing, Sales, and Application Support between both companies in the United States. Both Nexstim and Inomed will attend the American Association of Neurologic
- GlobeNewswire
Neurosurgery Customer from Germany Orders Nexstim NBS System 5
Press release, Helsinki, 26 April 2024 at 3 PM (EEST) Neurosurgery Customer from Germany Orders Nexstim NBS System 5 Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has received an order for a new NBS System 5 from an existing customer hospital in Germany. The system will be used in neurosurgery. The Nexstim Navigated Brain Stimulation (NBS) System 5 is indicated for non-invasive mapping of the primary motor cortex of the brain to its cortical gyrus and localization of cortical areas that do no
